Paladin Labs Inc. (TSX: PLB) business unit Paladin Biosciences division, has received a US$100,000 Grand Challenges Explorations grant from the Bill & Melina Gates Foundation. The grant is for the support of a global health research project conducted by Dr. Rajan George, the Chief Technology Officer of Paladin Biosciences. The project is entitled "Dendritic cell receptor-targeted malaria vaccines."
Get Rich Penny Stocks is a leading financial publication that is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
Dr. George's project is but one of 76 grants announced by the Gates Foundation in the third funding round of Grand Challenges Exploration. The grants were provided to scientist throughout the globe in 16 different countries.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB.
Sign up for the Free GetRichPennyStocks Newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
GetRichPennyStocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that could be on the brink of a breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
